Israel-based Xinteza has unveiled it has developed a non-Cannabaceae source for cannabinoid biosynthesis in research led by professor Asaph Aharoni at the Weizmann Institute of Science USA.
Biosynthesis technology company Xinteza has stated that it has expanded its IP portfolio with a breakthrough discovery of a novel, non-cannabis plant-derived production system.
The company claims that the system is capable of highly efficient and flawless end-to-end cannabinoid synthesis, tackling known enzymatic and modification bottlenecks and challenges in biosynthesis.
Read more: New research could help cultivators control THC and CBD levels in crops
The novel expression system contains cannabinoid enzymatic machinery throughout its entire botanical tissue mass, and has the potential to yield a higher active-ingredient-to-biomass ratio than cannabis plants.
Professor Asaph Aharoni, Xinteza’s scientific co-founder and head of the Weizmann Institute of Science Plant Metabolomics Lab and of the Institute’s Plant and Environmental Sciences Department, commented: “This discovery is a major milestone in the path to uncover and exploit rare and new cannabinoid molecules with potentially novel pharmacological activities.
”Moreover, this alternative non-Cannabaceae production system is significantly more amenable than cannabis to genetic engineering and cellular transformation, allowing greater flexibility in a range of biosynthesis enhancement and optimization processes.”
Biosynthesis technologies have the potential to revolutionise cultivation-and-extraction-based production methods of cannabinoid compounds for CPG and pharma. However, the development of these long-awaited cannabinoid biosynthesis processes has been slowed down and challenged by several enzymatic and genetic modification-related bottlenecks arising from the introduction of cannabis genes into microorganism-based fermentation systems.
The discovery of a non-Cannabaceae cannabinoid-producing botanical expression system has the potential to solve and mitigate some of these problems by initiating a novel toolkit of genes and enzymatic machinery.
By utilising this new toolkit, Xinteza aims to design novel pathways for cannabinoid biosynthesis, in order to achieve higher yields and efficiencies, better consistency, purity, and cost-effectiveness.
CEO of Xinteza API, Alon Gal, commented: “This revolutionary discovery places Xinteza at the forefront of cannabinoid sourcing and synthesis and is creating excitement in the field.
“The flexibility and efficacy of this extraordinary patent-pending alternative genetic system offers solutions to some of the burning delivery issues currently plaguing our industry.
“We will continue to advance our research and development of the most innovative and powerful biosynthesis of an array of high-value cannabinoids and to leverage our fast-growing library of genes, enzymes, and novel molecules, while advancing collaborations with leading players in the biosynthesis arena.”
[activecampaign form=31]
